Products for Research Use Only

NSC139021

CAT: 0804-HY-112158-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112158-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NSC139021 (ERGi-USU) is a RIOK2 inhibitor with anticancer activity. RIOK2 can highly selectively inhibit the growth of ERG-positive cancer cells with IC50s of 30-400 nM against cell lines. RIOK2 also causes cell cycle arrest and apoptosis in glioblastoma via induction of Skp2 and Skp2-p27/p21-Cyclin E/CDK2-pRb signaling[1][2].
CAS Number
1147-56-4
Product Name Alternative
ERGi-USU
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Ser/Thr Kinase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/NSC139021.html
Purity
99.86
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
OC1=C(/N=N/C2=NC=CS2)C3=CC=CC=C3C=C1
Molecular Formula
C13H9N3OS
Molecular Weight
255.30
Precautions
H302, H315, H319, H335
References & Citations
[1]Mohamed AA, et al. Identification of a small molecule that selectively inhibits ERG-positive cancer cell growth. Cancer Res. 2018 Apr 30. pii: canres.2949.2017.|[2]Yu M, et al. RIOK2 Inhibitor NSC139021 Exerts Anti-Tumor Effects on Glioblastoma via Inducing Skp2-Mediated Cell Cycle Arrest and Apoptosis. Biomedicines. 2021 Sep 17;9 (9) :1244.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported